{
    "organizations": [],
    "uuid": "7abfcee929f501335dc76480c7a532dbd6335598",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/01/pr-newswire-nordic-nanovector-appoints-malene-brondberg-as-vice-president-investor-relations-and-corporate-communications.html",
    "ord_in_thread": 0,
    "title": "Nordic Nanovector Appoints Malene Brondberg as Vice President, Investor Relations and Corporate Communications",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "OSLO, Norway, Feb. 1, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that Ms. Malene Brondberg has been appointed as Vice President, Investor Relations and Corporate Communications. Malene will lead the engagement and communication with the investment community, media and analysts.\nMalene brings over 20 years' experience, including her roles as a sell-side healthcare analyst and as Global Head of Research and member of the Executive Committee at the Nordic investment bank ABG Sundal Collier. Since 2011, Malene has worked as a management consultant within the financial sector, acting as an advisor in relation to investor relations and funding, and has held various interim management positions such as CEO, COO and Head of Compliance.\nMalene holds a Master's Degree in Economics and Business Administration from Aalborg University in Denmark. Originally from Denmark, Malene is currently located in London, UK.\nLuigi Costa, Chief Executive Officer of Nordic Nanovector, comments: \"We are delighted to welcome Malene to the team. Her international industry perspectives and experience will be extremely important in leading our communications to stakeholders globally as we continue working to generate evidence to enable regulatory approval and commercialisation of Betalutin速 and increase the company's value.\"\nMalene Brondberg added: \"I am very pleased to join Nordic Nanovector at this exciting time in the Company's development. I look forward to working with the team to build strong and durable relationships with investors, analysts and media, and to ensure we clearly communicate the company's progress and the value created both from a clinical and commercial perspective.\"\nFor further information, please contact:\nMalene Brondberg\nVP\nInvestor Relations and Corporate Communications\nTel/Cell: +44-7561-431-762\nEmail: ir@nordicnanovector.com\nMedia enquiries: Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)\nTel: +44-207-638-9571\nEmail: nordicnanovector@citigatedr.co.uk\nAbout Nordic Nanovector:\nNordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.\nNordic Nanovector's lead clinical-stage candidate is Betalutin速, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.\nThe Company aims to rapidly develop Betalutin速, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 2019.\nNordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin速 in core markets.\nThe Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.\nFurther information about the Company can be found at www.nordicnanovector.com\nThis information was brought to you by Cision http://news.cision.com\nhttp://news.cision.com/nordic-nanovector/r/nordic-nanovector-appoints-malene-brondberg-as-vice-president--investor-relations-and-corporate-comm,c2442583\nView original content: http://www.prnewswire.com/news-releases/nordic-nanovector-appoints-malene-brondberg-as-vice-president-investor-relations-and-corporate-communications-300591725.html\nSOURCE Nordic Nanovector",
    "published": "2018-02-01T09:55:00.000+02:00",
    "crawled": "2018-02-01T10:14:27.027+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "oslo",
        "norway",
        "nordic",
        "nanovector",
        "asa",
        "ose",
        "nano",
        "announces",
        "malene",
        "brondberg",
        "appointed",
        "vice",
        "president",
        "investor",
        "relation",
        "corporate",
        "communication",
        "malene",
        "lead",
        "engagement",
        "communication",
        "investment",
        "community",
        "medium",
        "analyst",
        "malene",
        "brings",
        "year",
        "experience",
        "including",
        "role",
        "healthcare",
        "analyst",
        "global",
        "head",
        "research",
        "member",
        "executive",
        "committee",
        "nordic",
        "investment",
        "bank",
        "abg",
        "sundal",
        "collier",
        "since",
        "malene",
        "worked",
        "management",
        "consultant",
        "within",
        "financial",
        "sector",
        "acting",
        "advisor",
        "relation",
        "investor",
        "relation",
        "funding",
        "held",
        "various",
        "interim",
        "management",
        "position",
        "ceo",
        "coo",
        "head",
        "compliance",
        "malene",
        "hold",
        "master",
        "degree",
        "economics",
        "business",
        "administration",
        "aalborg",
        "university",
        "denmark",
        "originally",
        "denmark",
        "malene",
        "currently",
        "located",
        "london",
        "uk",
        "luigi",
        "costa",
        "chief",
        "executive",
        "officer",
        "nordic",
        "nanovector",
        "comment",
        "delighted",
        "welcome",
        "malene",
        "team",
        "international",
        "industry",
        "perspective",
        "experience",
        "extremely",
        "important",
        "leading",
        "communication",
        "stakeholder",
        "globally",
        "continue",
        "working",
        "generate",
        "evidence",
        "enable",
        "regulatory",
        "approval",
        "commercialisation",
        "increase",
        "company",
        "value",
        "malene",
        "brondberg",
        "added",
        "pleased",
        "join",
        "nordic",
        "nanovector",
        "exciting",
        "time",
        "company",
        "development",
        "look",
        "forward",
        "working",
        "team",
        "build",
        "strong",
        "durable",
        "relationship",
        "investor",
        "analyst",
        "medium",
        "ensure",
        "clearly",
        "communicate",
        "company",
        "progress",
        "value",
        "created",
        "clinical",
        "commercial",
        "perspective",
        "information",
        "please",
        "contact",
        "malene",
        "brondberg",
        "vp",
        "investor",
        "relation",
        "corporate",
        "communication",
        "email",
        "ir",
        "medium",
        "enquiry",
        "mark",
        "andrew",
        "citigate",
        "dewe",
        "rogerson",
        "tel",
        "email",
        "nordicnanovector",
        "nordic",
        "nanovector",
        "nordic",
        "nanovector",
        "committed",
        "develop",
        "deliver",
        "innovative",
        "therapy",
        "patient",
        "address",
        "major",
        "unmet",
        "medical",
        "need",
        "advance",
        "cancer",
        "care",
        "company",
        "aspires",
        "become",
        "leader",
        "development",
        "targeted",
        "therapy",
        "haematological",
        "cancer",
        "nordic",
        "nanovector",
        "lead",
        "candidate",
        "novel",
        "arc",
        "designed",
        "advance",
        "treatment",
        "lymphoma",
        "nhl",
        "nhl",
        "indication",
        "substantial",
        "unmet",
        "medical",
        "need",
        "representing",
        "growing",
        "market",
        "forecast",
        "worth",
        "nearly",
        "usd",
        "billion",
        "company",
        "aim",
        "rapidly",
        "develop",
        "alone",
        "combination",
        "therapy",
        "treatment",
        "major",
        "type",
        "nhl",
        "targeting",
        "first",
        "regulatory",
        "submission",
        "follicular",
        "lymphoma",
        "nordic",
        "nanovector",
        "intends",
        "retain",
        "marketing",
        "right",
        "actively",
        "participate",
        "commercialisation",
        "core",
        "market",
        "company",
        "also",
        "advancing",
        "pipeline",
        "arc",
        "immunotherapy",
        "multiple",
        "cancer",
        "indication",
        "information",
        "company",
        "found",
        "information",
        "brought",
        "cision",
        "http",
        "http",
        "c2442583",
        "view",
        "original",
        "content",
        "http",
        "source",
        "nordic",
        "nanovector"
    ]
}